BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 3860296)

  • 1. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
    Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMSA--a promising new agent in refractory acute leukemia.
    Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
    Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of amsacrine gluconate in refractory leukemia.
    Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
    Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
    Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
    Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
    Van Echo DA; Wiernik PH; Aisner J
    Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and II study of m-AMSA in acute leukaemia.
    Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
    Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
    Naparstek E; Shinar E; Polliack A
    Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
    Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
    Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of AMSA in acute leukemia.
    Dupont JC; Garay GE; Scaghone C; Pavlovsky S; Woodley PV
    Cancer Treat Rep; 1982 Jul; 66(7):1596-7. PubMed ID: 7046933
    [No Abstract]   [Full Text] [Related]  

  • 16. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
    Arlin ZA
    Cancer Treat Rep; 1983 Nov; 67(11):967-70. PubMed ID: 6357436
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
    Miller LP; Miller DR; Tan CT
    Cancer Treat Rep; 1983 May; 67(5):439-43. PubMed ID: 6189604
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
    Marit G; David B; Reiffers J; Broustet A
    Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.